Biogen Idec Inc (BIIB) 319.37 $BIIB
Anti-Depressants: The Secret to Preventing Alzheimer's?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 31, 3:52PM CDT
The Science Translational Medicine journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories under the brand name Celexa, as a potential way to help slow down the development of...
Is This Really the Best Pipeline In Biotech?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 30, 7:21PM CDT
Any disappointment from ISIS Pharmaceuticals recent earnings has been forgotten. While Kynamro may not be selling to the degree investors hoped for, a clincial trial success for a new blood thinner has shares headed higher at the end of the month....
Apple, Facebook, Valeant Among 5 Top IBD 50 Big Caps
at Investor's Business Daily - Fri May 30, 6:55PM CDT
Apple rocked the market with its purchase of Beats Electronics on Wednesday. But the personal electronics giant's shares have been on the uptick since reporting strong quarterly sales on April 23. Apple is among the top big-cap stocks on the IBD 50....
The Zacks Analyst Blog Highlights: Facebook, AT&T, Array BioPharma, Biogen Idec and Celgene
PR Newswire - Fri May 30, 8:40AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Facebook (Nasdaq:FB-Free Report), AT&T (NYSE:T-Free Report), Array BioPharma (Nasdaq:ARRY-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report) andCelgene Corp. (Nasdaq:CELG-Free Report).
Data from Biogen Idec's Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses
Business Wire - Fri May 30, 6:30AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that more than 60 company-sponsored presentations highlighting key data from its industry-leading portfolio of marketed and investigational multiple sclerosis (MS) therapies are being featured during two neurology conferences, further demonstrating its commitment to meeting the individual needs of MS patients and improving outcomes with research that addresses important efficacy and safety questions.
Biogen Idec
at Investor's Business Daily - Thu May 29, 5:48PM CDT
Biogen Idec (BIIB) rose 4% after JPMorgan upgraded its stock to overweight from neutral, citing positive opinions on oral multiple-sclerosis drug Tecfidera, and hiked its price target to 375 from 300. JPMorgan cut Celgene (CELG) to neutral from...
Array BioPharma Collaborates with Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 29, 4:10PM CDT
Array BioPharma (ARRY) announced that it has entered into a drug discovery collaboration agreement with Biogen Idec (BIIB).
No. 1 Draft Pick: Tremendous Upside or Total Bust?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Thu May 29, 3:38PM CDT
We love to answer reader questions, so send yours to HC@Fool.com. Here's a recent submission to our mailbag: The NBA draft lottery was last night and Cleveland won the first overall pick again. If you were drafting a drug in development for your...
Biogen Upgraded, Celgene Downgraded On Pipelines
at Investor's Business Daily - Thu May 29, 2:18PM CDT
Big-cap biotechs Biogen Idec (BIIB) and Celgene (CELG) were headed in opposite directions on the stock market today after JPMorgan upgraded one and downgraded the other. JPMorgan analyst Geoff Meacham lifted his rating on Biogen to overweight from...
Trade-Ideas: Biogen Idec (BIIB) Is Today's Momo Momentum Stock
at The Street - Thu May 29, 12:20PM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Why Biogen Idec Inc. Shares Could Pop 20%
Brian Pacampara, The Motley Fool - Motley Fool - Thu May 29, 10:20AM CDT
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a look at particularly stock-shaking analyst upgrades and downgrades -- just in case their reasoning behind the call makes sense. ...
How Will Biogen Idec (BIIB) Stock React To This Analyst Upgrade?
at The Street - Thu May 29, 7:07AM CDT
Shares of Biogen Idec (BIIB) are higher in pre-market trade after J.P. Morgan (JPM) upgraded the stock to 'overweight' from 'neutral' and raised its price target to $375 from $300.
Upgrade Alert for Biogen Idec (BIIB)
Comtex SmarTrend(R) - Thu May 29, 7:00AM CDT
Biogen Idec (NASDAQ:BIIB) was upgraded from Neutral to Overweight at JP Morgan today. The stock closed yesterday at $308.81 on volume of 1.2 million shares, below average daily volume of 1.5 million. In the past 52 weeks, shares of Biogen Idec have traded between a low of $194.66 and a high of $358.89 and closed yesterday at $308.81, which is 59% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.3% while the 50-day MA has declined 0.4%.
Biogen Idec Foundation Awards The Possible Project with a $500,000 Grant to Support Youth Entrepreneurship
Business Wire - Thu May 29, 6:00AM CDT
The Biogen Idec Foundation has awarded a $500,000 grant to The Possible Project (TPP), a non-profit organization that teaches high school students how to start and run their own businesses through a tailored curriculum, and access to technology and to mentors from the local business community. The grant, payable over five years, will support TPP's new Makerspace, which will offer students a permanent incubator space for their businesses and provide the opportunity for real world application of TPP curriculum.
Array BioPharma enters into drug discovery collaboration with Biogen Idec for inflammatory diseases
M2 - Thu May 29, 3:06AM CDT
Biopharmaceutical company Array BioPharma (NasdaqGM :ARRY) reported on Wednesday an agreement for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders in collaboration with Biogen Idec (NasdaqGS:BIIB).
Biogen Idec 2014 Annual Shareholder Meeting Webcast
Business Wire - Wed May 28, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that its 2014 Annual Shareholder Meeting will be webcast live on Thursday, June 12, 2014 at 9:00 a.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available following the meeting.
Array BioPharma Announces Drug Discovery Collaboration Agreement With Biogen Idec
PR Newswire - Wed May 28, 8:00AM CDT
Array BioPharma (Nasdaq: ARRY) announced today a collaboration agreement with Biogen Idec (NASDAQ: BIIB) for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders.
Biogen Idec Announces Official Partnership with Sailing Sclerosis' "Oceans of Hope" to Globally Change Perceptions of MS
Business Wire - Wed May 28, 1:00AM CDT
In celebration of World MS Day and as part of its ongoing mission to support those living with Multiple Sclerosis (MS) globally, Biogen Idec (NASDAQ: BIIB) announced that it has joined the Sailing Sclerosis Foundation's (SSF) Oceans of Hope project as principal sponsor and official partner. This multi-year, global campaign is designed to use sailing as a means to educate and empower the MS community, changing perceptions of what it means to live with the disease and demonstrating the benefits of an active lifestyle.
Is Biogen Idec Inc a Buy?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue May 27, 5:30PM CDT
This year has turned against biotech investors, as the long-awaited correction came on hard in March and April. While conditions seem to have stabilized for the time being, Biogen Idec remains an outperformer as investors have slower...
Watch for Biogen Idec to Potentially Pullback After Gaining 3.36% Yesterday
Comtex SmarTrend(R) - Tue May 27, 4:05PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $299.50 to a high of $310.05. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $303.17 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Anti-Depressants: The Secret to Preventing Alzheimer's?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 31, 3:52PM CDT
The Science Translational Medicine journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories under the brand name Celexa, as a potential way to help slow down the development of...
Is This Really the Best Pipeline In Biotech?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 30, 7:21PM CDT
Any disappointment from ISIS Pharmaceuticals recent earnings has been forgotten. While Kynamro may not be selling to the degree investors hoped for, a clincial trial success for a new blood thinner has shares headed higher at the end of the month....
Apple, Facebook, Valeant Among 5 Top IBD 50 Big Caps
at Investor's Business Daily - Fri May 30, 6:55PM CDT
Apple rocked the market with its purchase of Beats Electronics on Wednesday. But the personal electronics giant's shares have been on the uptick since reporting strong quarterly sales on April 23. Apple is among the top big-cap stocks on the IBD 50....
The Zacks Analyst Blog Highlights: Facebook, AT&T, Array BioPharma, Biogen Idec and Celgene
PR Newswire - Fri May 30, 8:40AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Facebook (Nasdaq:FB-Free Report), AT&T (NYSE:T-Free Report), Array BioPharma (Nasdaq:ARRY-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report) andCelgene Corp. (Nasdaq:CELG-Free Report).
Data from Biogen Idec's Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses
Business Wire - Fri May 30, 6:30AM CDT
Biogen Idec (NASDAQ: BIIB) today announced that more than 60 company-sponsored presentations highlighting key data from its industry-leading portfolio of marketed and investigational multiple sclerosis (MS) therapies are being featured during two neurology conferences, further demonstrating its commitment to meeting the individual needs of MS patients and improving outcomes with research that addresses important efficacy and safety questions.
Biogen Idec
at Investor's Business Daily - Thu May 29, 5:48PM CDT
Biogen Idec (BIIB) rose 4% after JPMorgan upgraded its stock to overweight from neutral, citing positive opinions on oral multiple-sclerosis drug Tecfidera, and hiked its price target to 375 from 300. JPMorgan cut Celgene (CELG) to neutral from...
Array BioPharma Collaborates with Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 29, 4:10PM CDT
Array BioPharma (ARRY) announced that it has entered into a drug discovery collaboration agreement with Biogen Idec (BIIB).
No. 1 Draft Pick: Tremendous Upside or Total Bust?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Thu May 29, 3:38PM CDT
We love to answer reader questions, so send yours to HC@Fool.com. Here's a recent submission to our mailbag: The NBA draft lottery was last night and Cleveland won the first overall pick again. If you were drafting a drug in development for your...
Biogen Upgraded, Celgene Downgraded On Pipelines
at Investor's Business Daily - Thu May 29, 2:18PM CDT
Big-cap biotechs Biogen Idec (BIIB) and Celgene (CELG) were headed in opposite directions on the stock market today after JPMorgan upgraded one and downgraded the other. JPMorgan analyst Geoff Meacham lifted his rating on Biogen to overweight from...
Trade-Ideas: Biogen Idec (BIIB) Is Today's Momo Momentum Stock
at The Street - Thu May 29, 12:20PM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Why Biogen Idec Inc. Shares Could Pop 20%
Brian Pacampara, The Motley Fool - Motley Fool - Thu May 29, 10:20AM CDT
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a look at particularly stock-shaking analyst upgrades and downgrades -- just in case their reasoning behind the call makes sense. ...
How Will Biogen Idec (BIIB) Stock React To This Analyst Upgrade?
at The Street - Thu May 29, 7:07AM CDT
Shares of Biogen Idec (BIIB) are higher in pre-market trade after J.P. Morgan (JPM) upgraded the stock to 'overweight' from 'neutral' and raised its price target to $375 from $300.
Upgrade Alert for Biogen Idec (BIIB)
Comtex SmarTrend(R) - Thu May 29, 7:00AM CDT
Biogen Idec (NASDAQ:BIIB) was upgraded from Neutral to Overweight at JP Morgan today. The stock closed yesterday at $308.81 on volume of 1.2 million shares, below average daily volume of 1.5 million. In the past 52 weeks, shares of Biogen Idec have traded between a low of $194.66 and a high of $358.89 and closed yesterday at $308.81, which is 59% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.3% while the 50-day MA has declined 0.4%.
Biogen Idec Foundation Awards The Possible Project with a $500,000 Grant to Support Youth Entrepreneurship
Business Wire - Thu May 29, 6:00AM CDT
The Biogen Idec Foundation has awarded a $500,000 grant to The Possible Project (TPP), a non-profit organization that teaches high school students how to start and run their own businesses through a tailored curriculum, and access to technology and to mentors from the local business community. The grant, payable over five years, will support TPP's new Makerspace, which will offer students a permanent incubator space for their businesses and provide the opportunity for real world application of TPP curriculum.
Array BioPharma enters into drug discovery collaboration with Biogen Idec for inflammatory diseases
M2 - Thu May 29, 3:06AM CDT
Biopharmaceutical company Array BioPharma (NasdaqGM :ARRY) reported on Wednesday an agreement for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders in collaboration with Biogen Idec (NasdaqGS:BIIB).
Biogen Idec 2014 Annual Shareholder Meeting Webcast
Business Wire - Wed May 28, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that its 2014 Annual Shareholder Meeting will be webcast live on Thursday, June 12, 2014 at 9:00 a.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available following the meeting.
Array BioPharma Announces Drug Discovery Collaboration Agreement With Biogen Idec
PR Newswire - Wed May 28, 8:00AM CDT
Array BioPharma (Nasdaq: ARRY) announced today a collaboration agreement with Biogen Idec (NASDAQ: BIIB) for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders.
Biogen Idec Announces Official Partnership with Sailing Sclerosis' "Oceans of Hope" to Globally Change Perceptions of MS
Business Wire - Wed May 28, 1:00AM CDT
In celebration of World MS Day and as part of its ongoing mission to support those living with Multiple Sclerosis (MS) globally, Biogen Idec (NASDAQ: BIIB) announced that it has joined the Sailing Sclerosis Foundation's (SSF) Oceans of Hope project as principal sponsor and official partner. This multi-year, global campaign is designed to use sailing as a means to educate and empower the MS community, changing perceptions of what it means to live with the disease and demonstrating the benefits of an active lifestyle.
Is Biogen Idec Inc a Buy?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue May 27, 5:30PM CDT
This year has turned against biotech investors, as the long-awaited correction came on hard in March and April. While conditions seem to have stabilized for the time being, Biogen Idec remains an outperformer as investors have slower...
Watch for Biogen Idec to Potentially Pullback After Gaining 3.36% Yesterday
Comtex SmarTrend(R) - Tue May 27, 4:05PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $299.50 to a high of $310.05. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $303.17 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
